Health Care · Pharmaceutical Preparations

ELVN Enliven Therapeutics, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 1672619108 filings
Russell 2000

ELVN at a glance

Enliven Therapeutics, Inc. (ELVN, SEC CIK 1672619) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as November 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Enliven Therapeutics, Inc. (ELVN) shares worth $849.1 million in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Collins Helen Louise on November 17, 2026 of 61 shares at $47.60 per share.
  • In the last 90 days, ELVN insiders reported 0 open-market purchases ($0) and 11 open-market sales ($1.8M) on Form 4, a net sale of $1.8M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 11 sells
Net −$1.8M
13F holders
27 funds
$849.1M · +0 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: Clinical-stage biopharma developing selective small molecule therapeutics targeting validated biology using precision medicine
  • New emphasis on ELVN-001, a selective ATP-competitive BCR-ABL TKI for CML addressing resistance, off-target toxicity, and dosing challenges
  • Strategic pivot to prioritize ELVN-001; exploring strategic alternatives for ELVN-002 to focus resources on lead program
  • ENABLE Phase 1 trial enrolled 90 patients; 47% cumulative MMR rate by 24 weeks with favorable safety in heavily pretreated CML patients
  • CEO Rick Fair joined Dec 2025, bringing 25+ years pharma leadership including commercial launches for $23B oncology portfolio

Risk Factors

  • FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies
  • Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact
  • Supply chain vulnerability: changes in manufacturing process require FDA comparability analysis and approval, possibly delaying clinical trials
  • Competitive risk: dependency on ELVN-001 amid high biopharma attrition rates and competing therapies impacting commercial acceptance
  • Financial risk: accumulated deficit $347.2M, net loss $103.7M in 2025, need for substantial additional funding to sustain operations

Management Discussion & Analysis

  • No revenue generated in FY 2025 or 2024; no expected revenue in foreseeable future
  • Net loss $103.7M in 2025 vs $89.0M in 2024; operating expenses $119.7M vs $104.6M; operating margin negative and worsening
  • R&D increased to $85.9M in 2025 from $80.8M in 2024; ELVN-001 external costs up $7.8M, ELVN-002 external costs down $12.8M; G&A rose to $33.8M from $23.8M driven by $9.6M higher stock comp
  • Cash, cash equivalents and marketable securities $462.6M at December 31, 2025; raised $230M in June 2025 Public Offering, $90M in March 2024 Private Placement, $40M via Sales Agreement through 12/31/2025
  • Management expects operating losses and R&D expenses to increase; cash runway covers at least next 12 months; key risks include clinical trial progress, regulatory approval, need for further capital raises, and macroeconomic/geopolitical uncertainties

AI summary of the ELVN 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no product or other revenue
  • Operating margin not applicable, operating loss $36.0M vs $25.1M YoY
  • Relcobatinib R&D $12.0M vs $4.7M, strongest program; ELVN-002 $1.0M vs $2.3M
  • Cash, equivalents and securities $884.4M; operating cash use $50.4M for nine months
  • 2026 Public Offering net proceeds $432.8M; funding sufficient for at least 12 months, additional capital needed thereafter

Risk Factors

  • Newly emphasized FDA disruption risk triggered by agency layoffs, reorganization and budget constraints, potentially delaying reviews and inspections
  • Most materially updated pricing risk, CMS GLOBE Model Final Rule requires international-price-linked Part B rebates beginning April 1, 2027
  • Companion-diagnostic compliance risk, FDA LDT rule litigation may alter validation, labeling and reimbursement requirements
  • Near-term clinical risk, CML enrollment constrained by Scemblix approval and competing trials
  • Financial risk, $83.8 million nine-month net loss and $431.0 million accumulated deficit underscore continued capital needs

AI summary of the ELVN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Press release announces Enliven Therapeutics’ financial results for the quarter ended September 30, 2026
  • Detailed financial figures and management commentary are contained in Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • FDA alignment on ENABLE-2 final design reduces regulatory uncertainty ahead of pivotal Phase 3 launch before year-end 2026
  • Planned trial: approximately 450 patients, relcobatinib 80 mg versus investigator-selected second-generation TKI
Filed Oct 14, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Kristine Ball appointed to Enliven’s board, adding biotechnology expertise in finance, strategy, governance and commercial readiness
  • Appointment supports planned transition from clinical development toward commercialization

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Board expanded from seven to eight directors, adding Kristine Ball as a Class II director through the 2028 annual meeting
  • Ball joins the Audit Committee, strengthening board-level financial oversight

Item 7.01: Regulation FD Disclosure

  • Board appointment of Ms. Ball announced October 14, 2026
  • Leadership addition may influence governance and strategic oversight
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 2026 Phase 1 data support ELVN-001 advancement, with 61% overall MMR and 48% MMR by 24 weeks at 80 mg QD
  • Earlier-line patients showed 67% overall MMR and 55% MMR by 24 weeks, strengthening the targeted Phase 3 opportunity

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results for quarter ended June 30, 2026 announced August 5, 2026
  • Detailed financial results and management commentary contained in Exhibit 99.1

AI summaries of ELVN 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ELVN

Don't miss the next ELVN filing

  • Alerts as it files. A push when ELVN files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ELVN, by share count.
  • Ask anything. An AI agent that reads every ELVN filing and answers with sources.

ELVN alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Collins Helen LouiseSellNov 17, 2026$47.60
Collins Helen LouiseMNov 17, 2026$2.48
Collins Helen LouiseSellNov 17, 2026$46.83
Collins Helen LouiseMNov 17, 2026-
Kunkel Lori AnneMOct 30, 2026$18.30
Kunkel Lori AnneMOct 30, 2026$1.12
Kunkel Lori AnneMOct 30, 2026-
Kunkel Lori AnneMOct 30, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$83.5M-$104.6M-$119.7M
Net Income-$71.6M-$89.0M-$103.7M
Balance Sheet
Total Assets$271.9M$325.8M$476.2M
Equity$245.9M$309.8M$459.6M
ROE-29.1%-28.7%-22.6%
Per Share
EPS$-2.01$-1.89$-1.83
Cash Flow
Operating CF-$61.3M-$73.2M-$70.3M

Source: XBRL data in Enliven Therapeutics, Inc. (ELVN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ELVN share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ELVN shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$849.1M
Q2 202627$1.39B
Q1 202625$747.3M
Q4 202521$292.6M
Q3 202523$393.0M
Q2 202522$379.5M
Q1 202518$241.3M
Q4 202414$269.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 177 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ELVN filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 19, 2026--
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Nov 3, 2026--
4Oct 21, 2026--
4Oct 21, 2026--
4Oct 16, 2026--
8-KOct 14, 2026Analysis-
4Oct 5, 2026--
4Sep 21, 2026--
4Sep 21, 2026--
4Aug 19, 2026--
4Aug 19, 2026--
4Aug 6, 2026--
8-KAug 5, 2026Analysis-
10-QAug 5, 2026Analysis
4Jul 21, 2026--
4Jul 21, 2026--
4Jul 8, 2026--
4Jun 24, 2026--
4Jun 22, 2026--
4Jun 22, 2026--
4Jun 17, 2026--
8-KJun 12, 2026Analysis-
8-KJun 11, 2026Analysis-

Related Health Care companies

All Health Care →

ELVN SEC filings: frequently asked questions

Are ELVN insiders buying or selling?

In the last 90 days, Enliven Therapeutics, Inc. (ELVN) officers, directors and 10% owners reported no open-market purchases and 11 open-market sales worth $1.8 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold ELVN stock?

As of September 30, 2026, the largest Enliven Therapeutics, Inc. (ELVN) holders among the 13F filers tracked by SignalX were BlackRock ($261.8 million), Vanguard Capital Management LLC ($132.6 million), T. Rowe Price Group ($107.7 million), State Street Corp ($70.8 million), Citadel Advisors LLC ($57.0 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the main risks in ELVN's latest 10-K?

In the 10-K filed March 3, 2026, Enliven Therapeutics, Inc. (ELVN) flagged: FDA regulatory risk: potential delays or denials if ELVN-001 clinical trial design or data interpretation not accepted, requiring additional clinical studies. Geopolitical exposure: clinical development reliant on sites in U.S., Europe and China, subject to global trade tensions and tariffs impact. (AI summary of the Risk Factors section.)

What did ELVN report in its latest 8-K?

Enliven Therapeutics, Inc. (ELVN) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Press release announces Enliven Therapeutics’ financial results for the quarter ended September 30, 2026.

What are the latest ELVN SEC filings?

Enliven Therapeutics, Inc. (ELVN) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on November 19, 2026.

What is ELVN's SEC CIK number?

Enliven Therapeutics, Inc. (ELVN)'s SEC Central Index Key (CIK) is 1672619. EDGAR lists every ELVN filing under that number.

Ask anything about ELVN

The research agent reads ELVN's filings, financials, insider trades and 13F holders, then answers with sources.